QuidelOrtho Considers Divesting Testing Unit Amid Significant Share Decline
QuidelOrtho is reportedly exploring the sale of its testing unit as its shares have plummeted 90% since the initial approval of its Covid-19 rapid antigen tests.
Editorial Staff
1 min read
Updated 3 days ago
QuidelOrtho, a diagnostic company, is looking into the possibility of selling its testing unit. This move comes as the company faces a dramatic decline in its stock value.
The company's shares have decreased by 90% since it received the first approval for its rapid antigen tests for Covid-19. This significant drop raises concerns about its market position.
As private equity firms show interest in healthcare companies, QuidelOrtho's potential sale could attract attention. However, the future remains uncertain as the company navigates this challenging landscape.